MRNA News and Press, Moderna Inc. From 02/27/26

2026-02-27 09:27:55 ET More on Moderna Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript Moderna, Inc. 2025 Q4 - Results - Earnings Call Presentation Moderna: FDA RTF Derails mRNA-1010 And Reignites The Sell Case CDC advisory meeting in March to focus on ...

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive CHMP opinion mCOMBRIAX will be made available in the European Union, subject to final Europe...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...

2026-02-26 12:27:26 ET More on Pfizer, BioNTech, etc. BioNTech: The Market Is Pricing Low Oncology Success Pfizer: A Risky 6.3% Yield For Income-Oriented Investors Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Novavax...

2026-02-25 14:18:50 ET More on markets The Fed Is Bracing For An AI Bubble Burst And Global Stagflation S&P 500, Trump, And The Markets: The Scorecard So Far, Where To Look Next Softer Inflation And Expectations For Stronger Q1 Economic Growth Push The Fed Toward...

2026-02-25 08:35:00 ET Moderna (NASDAQ: MRNA) soared into the spotlight during the pandemic thanks to its mRNA technology and its rapid development of a coronavirus vaccine. But it's those two elements that have weighed on the stock in more recent times: The U.S. last year ended abo...

2026-02-25 07:19:21 ET More on Pfizer, Merck, etc. Merck: Why Investors Should Remain Bullish Despite Patent Risks Pfizer: A Risky 6.3% Yield For Income-Oriented Investors Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) ...

2026-02-24 12:06:38 ET More on Pfizer, Merck, etc. Merck: Why Investors Should Remain Bullish Despite Patent Risks Pfizer: A Risky 6.3% Yield For Income-Oriented Investors Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) ...

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled r...

2026-02-23 09:20:00 ET Moderna (NASDAQ: MRNA) became a household name during the coronavirus pandemic. There's a good reason for that: Its mRNA technology enabled the rapid development of a vaccine. The financial benefit of that success for Moderna was huge, but what comes next? ...